Table 2 Characteristics of patients who intensified metformin therapy

N

63,551

4942

6169

1275

Age, years median IQR^a

62 (56.5, 70.9)

65 (57.3, 73.9)

61 (54.7, 69.3)

66 (58.4, 76.7)

Male, (%)

96

95

95

96

 White

74

78

68

74

 Black

14

10

21

18

 Other

4

6

5

5

Months to intensification^a

18 (6, 37)

11 (4, 23)

13 (3, 34)

31 (18, 49)

Systolic Blood Pressure, mmHg^a

132 (121, 142)

132 (120, 142)

130 (119, 142)

130 (119, 142)

Creatinine, mg/dL^a

1.0 (0.9, 1.2)

1.0 (0.9, 1.2)

1.0 (0.9, 1.2)

1.1 (0.9, 1.3)

Hospitalized in the last year,%

17.8

17.7

42.9

50.6

Number of outpatient visits^a

6 (4, 11)

5 (3, 9)

7 (4, 13)

6 (3, 12)

 Malignancy

9

8

12

16

 Liver/Respiratory disease

4

3

10

18

 Congestive heart failure

8

6

13

24

 Cardiovascular disease

32

33

38

52

 Serious Mental illness

28

23

36

38

 Arrhythmia

11

10

14

25

 COPD/Asthma

17

14

24

32

 Smoking

19

14

24

28

 ACE/ARB

71

69

67

52

 Antihypertensives

74

73

73

67

 Antiarrhythmics

2

2

4

4

 Anti-coagulants

13

16

18

24

 Statins/lipid lowering drugs

78

77

70

55

 Nitrates

11

11

14

13

 Aspirin

24

19

30

23

 Loop diuretics

13

12

22

24